Osivax
Osivax initiates phase 2b trial of influenza A vaccine candidate
The study aims to enrol 2,850 participants across 16 sites in Europe
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
More than 600,000 people in the US were hospitalised due to flu-related illness last year
Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines
The combined vaccine approach could simplify immunisation practices and lead to higher uptake
Seven strategic steps to enhance patient recruitment & retention in your influenza studies
The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...
Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study
The serious adverse event reported was found to be unrelated to the vaccine
Is your influenza clinical trial prepared for the upcoming flu season? Part 3
This blog will discuss some important aspects to consider to maximise patient retention on your flu clinical trials. For more information on patient recruitment considerations, check out our previous blogs...
Is your influenza clinical trial prepared for the upcoming flu season? Part 2
Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and resulting in financial losses for sponsors and research sites (Rangu and Maxwell,...
Is your influenza clinical trial prepared for the upcoming flu season? Part 1
The Northern Hemisphere flu season is fast approaching, bringing with it a multitude of challenges for respiratory clinical trials. The exact dates of the flu season in the Northern Hemisphere...
GSK’s mRNA seasonal flu vaccine shows promise in younger and older adults
The company said it will now progress the programme into late-stage clinical development
Pfizer and BioNTech share late-stage results for COVID-19/flu combination vaccine
The combined vaccine approach could simplify immunisation practices and lead to higher uptake
Patient Recruitment & Retention Webinar for Influenza Studies
Join the upcoming webinar which will discuss key patient recruitment & retention challenges and solutions for upcoming influenza studies.
GSK and CureVac restructure current mRNA collaboration in deal worth over €1.4bn
The companies have been working together to develop mRNA vaccines for infectious diseases since 2020